102
Views
0
CrossRef citations to date
0
Altmetric
Articles

Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020

ORCID Icon, , , , , , & ORCID Icon show all
Pages 43-47 | Received 28 Apr 2022, Accepted 29 Sep 2022, Published online: 02 Nov 2022

References

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021 Jul;71(4):359]. CA A Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654.
  • National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Lung and Bronchus Cancer, 2018. https://seer.cancer.gov/statfacts/html/lungb.html
  • American Lung Association State of Lung Cancer. Racial and Ethnic Disparities. 2021. lung.org/research/state-of-lung-cancer/racial-and-ethnic-disparities
  • Wisnivesky JP, McGinn T, Henschke C, Hebert P, Iannuzzi MC, Halm EA. Ethnic disparities in the treatment of stage I non-small cell lung cancer. Am J Respir Crit Care Med. 2005;171(10):1158–1163. doi:10.1164/rccm.200411-1475OC.
  • Hardy D, Liu C-C, Xia R, Cormier JN, Chan W, White A, et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer. 2009;115(10):2199–2211. doi:10.1002/cncr.24248.
  • Ha SY, Choi S-J, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget. 2015;6(7):5465–5474. doi:10.18632/oncotarget.2925.
  • Lythgoe MP, Krell J, Savage P, Prasad V. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020. Prostate Cancer Prostatic Dis. 2021;24(4):1208–1211. doi:10.1038/s41391-021-00361-0.
  • Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870. doi:10.1001/jamaoncol.2019.1870.
  • Lythgoe MP, Krell J, Kenny L, Khaki AR. Racial diversity and reporting in FDA registration trials for breast cancer from 2006 to 2021. Ann Oncol. 2021;32(Supplement 2):S88. doi:10.1016/j.annonc.2021.03.171.
  • Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263–273. doi:10.1002/cpt.61.
  • Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62. doi:10.1038/bjc.2013.721.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.